Search
Royalty Pharma PLC
RPRXAdd to Watchlist
58.440USD
-0.580-0.98%
Close 07-31 16:00（ET）Quotes delayed by 15 min
25.93BMarket Cap
30.42P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Royalty Pharma PLC is 8.40, ranking 38 out of 155 in the Pharmaceuticals industry. The average price target is 45.00, with a high of 56.00 and a low of 34.67.
Analyst Rating
Based on
10
analysts
Buy
Current Rating
60.304
Target Price
+1.90%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Royalty Pharma PLC
RPRX
10
Biogen Inc
BIIB
38
Amgen Inc
AMGN
38
Eli Lilly and Co
LLY
34
AbbVie Inc
ABBV
33
Pfizer Inc
PFE
32
1
2
3
...
32
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Royalty Pharma PLC's expected revenue for the next quarter?
Royalty Pharma PLC's expected revenue is 693.19M.
What is Royalty Pharma PLC's price target?
Analysts forecast that Royalty Pharma PLC's price target is USD 45.00, with the highest forecast at USD 56.00 and the lowest forecast at USD 34.67.
How have Royalty Pharma PLCRPRX's recent earnings per share performed?
The market expectation was USD 0.67, while Royalty Pharma PLCRPRX's earnings per share (EPS) for the previous quarter was USD 0.50. EPS for the next quarter is expected at USD 1.28.
What is the analyst rating for Royalty Pharma PLC?
Based on the ratings of Royalty Pharma PLC's stock from 10 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.